Oncotelic updates on OT-101 biomarker program pursuing accelerated approval route for solid tumors

Oncotelic Therapeutics, Inc.

New corporate presentation highlights OT-101 biomarker program with pembrolizumab in multiple phase 2 trials.
Aims to leverage FDA accelerated approval pathway for TMB-H solid tumors, similar to pembrolizumab's June 2020 approval.
Phase 2 trials target solid tumors with high-TGF signature, using a companion diagnostic assay.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.